NEUROCRINE BIOSCIENCES Trademark

Trademark Overview

On Monday, August 16, 2021, a trademark application was filed for NEUROCRINE BIOSCIENCES with the United States Patent and Trademark Office. The USPTO has given the NEUROCRINE BIOSCIENCES trademark a serial number of 90981369. The federal status of this trademark filing is SU - REGISTRATION REVIEW COMPLETE as of Thursday, April 3, 2025. This trademark is owned by Neurocrine Biosciences, Inc.. The NEUROCRINE BIOSCIENCES trademark is filed in the Pharmaceutical Products and Medical & Beauty Services & Agricultural Services categories with the following description:

Pharmaceutical preparations for human use for treatment of neuroendocrinological diseases, disorders, and conditions; Pharmaceutical preparations for the treatment of hormonal and genetic diseases, disorders and conditions; pharmaceuticals for human use for the treatment of rare and orphan diseases, disorders and conditions; pharmaceutical preparations for the treatment of congenital adrenal hyperplasia

providing medical information in the field of hormonal and genetic diseases, disorders and conditions; on-line information services, namely, providing medical information in the field of hormonal and genetic diseases, disorders and conditions
neurocrine biosciences

General Information

Serial Number90981369
Word MarkNEUROCRINE BIOSCIENCES
Filing DateMonday, August 16, 2021
Status819 - SU - REGISTRATION REVIEW COMPLETE
Status DateThursday, April 3, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, December 13, 2022

Trademark Statements

Description of MarkThe mark consists of a stylized circular spiral design with "NEUROCRINE" above "BIOSCIENCES" in block lettering to the right.
Goods and ServicesPharmaceutical preparations for human use for treatment of neuroendocrinological diseases, disorders, and conditions; Pharmaceutical preparations for the treatment of hormonal and genetic diseases, disorders and conditions; pharmaceuticals for human use for the treatment of rare and orphan diseases, disorders and conditions; pharmaceutical preparations for the treatment of congenital adrenal hyperplasia
Indication of Colors claimedColor is not claimed as a feature of the mark.
Goods and Servicesproviding medical information in the field of hormonal and genetic diseases, disorders and conditions; on-line information services, namely, providing medical information in the field of hormonal and genetic diseases, disorders and conditions
NOT AVAILABLE"BIOSCIENCES"

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, October 5, 2021
Primary Code005
First Use Anywhere DateSaturday, December 21, 2024
First Use In Commerce DateSaturday, December 21, 2024
International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, October 5, 2021
Primary Code044
First Use Anywhere DateWednesday, April 24, 2024
First Use In Commerce DateWednesday, April 24, 2024

Trademark Owner History

Party NameNeurocrine Biosciences, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92130
Party NameNeurocrine Biosciences, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92130

Trademark Events

Event DateEvent Description
Wednesday, October 6, 2021NOTICE OF DESIGN SEARCH CODE E-MAILED
Tuesday, May 3, 2022ASSIGNED TO EXAMINER
Thursday, May 5, 2022COMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION AUTOMATIC ENTRY
Thursday, May 5, 2022EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED
Thursday, August 19, 2021NEW APPLICATION ENTERED
Tuesday, October 5, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, November 5, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, December 13, 2022PUBLISHED FOR OPPOSITION
Tuesday, December 13, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, February 7, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, May 5, 2022EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
Wednesday, November 23, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, May 5, 2022NOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
Saturday, November 5, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, November 4, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, November 4, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, July 20, 2023TEAS REQUEST TO DIVIDE RECEIVED
Thursday, July 20, 2023SOU EXTENSION 1 FILED
Wednesday, August 9, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, August 17, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, January 17, 2024SOU EXTENSION 2 GRANTED
Wednesday, January 17, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, January 17, 2024SOU EXTENSION 2 FILED
Friday, January 19, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, July 20, 2023SOU TEAS EXTENSION RECEIVED
Thursday, July 20, 2023DIVISIONAL REQUEST RECEIVED
Thursday, August 17, 2023CORRECTED NOA E-MAILED
Wednesday, August 16, 2023DIVISIONAL PROCESSING COMPLETE
Wednesday, August 16, 2023SOU EXTENSION 1 GRANTED
Friday, August 2, 2024DIVISIONAL REQUEST RECEIVED
Friday, August 2, 2024SOU EXTENSION 3 FILED
Friday, August 2, 2024SOU TEAS EXTENSION RECEIVED
Friday, August 2, 2024TEAS REQUEST TO DIVIDE RECEIVED
Wednesday, September 25, 2024SOU EXTENSION 3 GRANTED
Wednesday, September 25, 2024DIVISIONAL PROCESSING COMPLETE
Wednesday, September 25, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, September 25, 2024CORRECTED NOA E-MAILED
Thursday, February 6, 2025DIVISIONAL REQUEST RECEIVED
Thursday, February 6, 2025TEAS STATEMENT OF USE RECEIVED
Thursday, February 6, 2025TEAS REQUEST TO DIVIDE RECEIVED
Thursday, February 6, 2025USE AMENDMENT FILED
Wednesday, February 26, 2025STATEMENT OF USE PROCESSING COMPLETE
Wednesday, February 26, 2025DIVISIONAL PROCESSING COMPLETE
Thursday, March 20, 2025TEAS CHANGE OF OWNER ADDRESS RECEIVED
Thursday, March 20, 2025TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, March 24, 2025ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, April 3, 2025ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Thursday, April 3, 2025NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Monday, March 24, 2025TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, March 20, 2025APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Monday, March 24, 2025TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

Related Keywords

biosciences neurocrine disorders diseases conditions treatment pharmaceutical information hormonal genetic preparations medical